REFERENCES
- Palella FJ, Delaney KM, Moorman AC, et al. Declining mor-tality and morbidity in HIV-infected ambulatory patients. New Engl J Med. 1998;338:853–860.
- US Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; October 10, 2006. Available at http://AIDSinfo.nih.gov.
- Hammer S, Saag M, Schechter M, Montaner J, Scholley R, et al. Treatment for Adult HIV Infection. 2006 recommenda-tions of the International AIDS Society-USA Panel. JAMA. 2006;296:827–843.
- Palella FJ, Moorman AC, Chmiel J, Chan C, Holmberg SD, HIV Outpatient Study Investigators. Durability and predictors of success of highly active antiretroviral therapy (ART) for ambulatory HIV-infected patients. AIDS. 200216: 1617–1627.
- Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral naïve patients: a 3 year randomized trial. JAMA. 2004;292: 191–201.
- National Institutes of Allergy and Infectious Diseases. Divi-sion of AIDS Table of Grading Severity of Adult Adverse Experiences. August 1992. Available at http://rcc.tech-res-intl.com.
- Cockcroft DW, Gault MH. Prediction of creatinine clear-ance from serum creatinine. Nephron. 1976;16:31–41.
- Levy S, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461–470.
- Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, em-tricitabine and efavirenz vs. zidovudine, lamivudine and efavirenz for HIV. N Engl J Med. 2006;3: 251–260.
- Molina JM, Wilkins A, Domingo P, Myers R, et al. Once daily vs. twice-daily lopinavir/ritonavir in antiretroviral-naive patients: 96-week results. Presented at: Third In-ternational AIDS Society Conference; July 2005. Abstract WePE12.3C12.
- Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir-containing highly active antiretroviral therapy regimens: a cohort and case-control study. J Acquir Im-mune Defic Syndr 2004;37:1489–1495.
- Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared to nucleoside reverse transcriptase inhibitor treatment. Clin Infect Dis. 2005;40:1194–1197.
- Gallant JE, Parish MA, Keruly JC, Moore RD. Tenofovir and changes in renal function: reply to Gupta [letter]. Clin Infect Dis. 2005;41:571.
- Moore RD, Keruly JC, Gallant JE. Tenofovir and renal dys-function in clinical practice. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; February 2007. Poster 832.
- Scott JD, Wolfe PR, Bolan RK, Guyer W. Serious renal im-pairment occurs rarely with use of tenofovir DF. HIV Clin Trials. 2006;7:55–58.
- NIH Consensus Development Panel on Osteoporosis Pre-vention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285: 785–795.